Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate CAS 152628-01-8 Purity >99.0% (HPLC) Telmisartan Intermediate Factory

Short Description:

Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate

CAS: 152628-01-8

Purity: >99.0% (HPLC) 

Appearance: White Powder

Intermediate of Telmisartan (CAS: 144701-48-4)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate
Synonyms Telmisartan Impurity 31; 3-Methyl-4-Butyrylamido-5-Nitro Benzoic Acid Methyl Ester; 4-Butyrylamino-3-methyl-5-nitrobenzoic Acid Methyl Ester
CAS Number 152628-01-8
CAT Number RF-PI1881
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C13H16N2O5
Molecular Weight 280.28
Melting Point  151.0~153.0℃
Density 1.265
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White Powder
Purity / Analysis Method >99.0% (HPLC)   
Loss on Drying <1.00%
Residue on Ignition <0.50%
Total Impurities <1.00%
Heavy Metals (as Pb) <20ppm
Test Standard Enterprise Standard
Usage Intermediate of Telmisartan (CAS: 144701-48-4)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate (CAS: 152628-01-8) is a useful synthetic intermediate in the production of Telmisartan (CAS: 144701-48-4), an antihypertensive drug. Methyl 4-(Butyrylamino)-3-Methyl-5-Nitrobenzoate is part of a more efficient process of synthesizing Telmisartan in terms of impurity, yield, cost, and large-scale production. Telmisartan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors.

  • Write your message here and send it to us